Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Um estudo de Sotatercept para o tratamento de Cpc-PH devido a ICFEP (MK-7962-007/A011-16) (CADENCE)

28 de agosto de 2026 atualizado por: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA

Um estudo de Fase 2, duplo-cego, randomizado, controlado por placebo para avaliar os efeitos do Sotatercept versus placebo para o tratamento da hipertensão pulmonar pós-capilar e pré-capilar combinada (Cpc-PH) devido a insuficiência cardíaca com fração de ejeção preservada (HFpEF)

This is a Phase 2, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of sotatercept versus placebo in adults with Cpc-PH due to HFpEF.

The objective of this study is to evaluate the efficacy, safety and tolerability of sotatercept versus placebo in adults with Cpc-PH due to HFpEF. Efficacy is measured by change from baseline in pulmonary vascular resistance (PVR, primary endpoint) and 6-minute walk distance (6MWD, key secondary endpoint).

Visão geral do estudo

Status

Concluído

Condições

Intervenção / Tratamento

Descrição detalhada

Participants enrolled in the study will have a diagnosis of Cpc-PH due to HFpEF with New York Heart Association (NYHA) functional class (FC) II or III. Participants will be randomly assigned in a 1:1:1 ratio to 1 of the 3 treatment groups (placebo, 0.3mg/kg sotatercept and 0.7mg/kg sotatercept) during the placebo-controlled Treatment Period. In the extension phase, sotatercept-treated participants will continue on their current dose. Placebo participants will be re-randomized in a 1:1 ratio to one of the two sotatercept treatment groups utilized in the placebo-controlled Treatment Period. Each participant will be enrolled in the study for up to 114 weeks, including a 28-day Screening Period, a 24-week, double-blind, placebo-controlled Treatment Period, an 18-month Extension Period, and an 8-week Follow-up Period.

As of protocol amendment 6, the 18-month Extension Period is being removed. Participants who have completed at least the 24-week placebo controlled treatment period and the end of study visit, and who have not discontinued study treatment early, may be eligible to participate in an extension study.

Tipo de estudo

Intervencional

Inscrição (Real)

165

Estágio

  • Fase 2

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

  • Alemanha
      • Berlin, Alemanha, 14050
        • DRK Kliniken Berlin Westend ( Site 1507)
    • Baden-Wurttemberg
      • Heidelberg, Baden-Wurttemberg, Alemanha, 69126
        • Thoraxklinik-Heidelberg gGmbH ( Site 1509)
    • Bavaria
      • München, Bavaria, Alemanha, 80639
        • Krankenhaus Neuwittelsbach ( Site 1510)
      • Regensburg, Bavaria, Alemanha, 93053
        • University Hospital Regensburg ( Site 1503)
    • Hesse
      • Bad Nauheim, Hesse, Alemanha, 61231
        • Kerckhoff-Klinik-Forschungs-GmbH ( Site 1514)
      • Giessen, Hesse, Alemanha, 35392
        • Universitätsklinikum Gießen und Marburg GmbH ( Site 1512)
    • Lower Saxony
      • Hanover, Lower Saxony, Alemanha, 30625
        • Medizinische Hochschule Hannover ( Site 1505)
    • North Rhine-Westphalia
      • Cologne, North Rhine-Westphalia, Alemanha, 50931
        • Uniklinik Köln ( Site 1511)
    • Rhineland-Palatinate
      • Mainz, Rhineland-Palatinate, Alemanha, 55131
        • Universitaetsmedizin Johannes Gutenberg Universitaet Mainz ( Site 1515)
    • Saxony
      • Dresden, Saxony, Alemanha, 01307
        • Universitätsklinikum Carl Gustav Carus an der TU Dresden. ( Site 1501)
  • Bélgica
    • Bruxelles-Capitale, Region de
      • Anderlecht, Bruxelles-Capitale, Region de, Bélgica, 1070
        • Hôpital Erasme ( Site 1402)
    • Vlaams-Brabant
      • Leuven, Vlaams-Brabant, Bélgica, 3000
        • UZ Leuven - Campus Gasthuisberg ( Site 1401)
  • Canadá
    • Alberta
      • Edmonton, Alberta, Canadá, T6G 2B7
        • University Of Alberta ( Site 2101)
    • Ontario
      • Hamilton, Ontario, Canadá, L8L 2X2
        • Hamilton General Hospital-Special Immunology Services Clinic ( Site 2110)
      • Toronto, Ontario, Canadá, M5G 2N2
        • University Health Network ( Site 2109)
    • Quebec
      • Sainte-Foy, Quebec, Canadá, G1V 4G5
        • Institut Universitaire de Cardiologie et de Pneumologie ( Site 2107)
  • Espanha
      • Barcelona, Espanha, 08036
        • Hospital Clinic de Barcelona ( Site 1602)
      • Madrid, Espanha, 28041
        • Hospital Universitario 12 de Octubre ( Site 1603)
      • Seville, Espanha, 41009
        • Hospital Universitario Virgen Macarena ( Site 1612)
      • Toledo, Espanha, 41007
        • Hospital Universitario de Toledo ( Site 1607)
    • Madrid
      • Majadahonda, Madrid, Espanha, 28222
        • Hospital Universitario Puerta de Hierro (Majadahonda) ( Site 1604)
    • Malaga
      • Marbella, Malaga, Espanha, 29603
        • Hospital Costa del Sol ( Site 1613)
  • Estados Unidos
    • Arizona
      • Phoenix, Arizona, Estados Unidos, 85032
        • PULMONARY ASSOCIATES, P.A. ( Site 1008)
      • Tucson, Arizona, Estados Unidos, 85724-0001
        • University of Arizona ( Site 1006)
    • California
      • La Jolla, California, Estados Unidos, 92037-1205
        • Scripps Clinic ( Site 4001)
      • Los Angeles, California, Estados Unidos, 90048
        • Cedars Sinai Medical Center ( Site 1082)
      • Orange, California, Estados Unidos, 92868
        • University of California Irvine ( Site 1086)
      • Santa Barbara, California, Estados Unidos, 93105-5311
        • Jeffrey S.Sager MD Medical Corporation ( Site 1060)
      • Stanford, California, Estados Unidos, 94305
        • Stanford University ( Site 1024)
      • Torrance, California, Estados Unidos, 90502
        • Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center ( Site 1028)
    • Colorado
      • Aurora, Colorado, Estados Unidos, 80045
        • University Of Colorado ( Site 1013)
      • Littleton, Colorado, Estados Unidos, 80120
        • South Denver Cardiology Associates ( Site 1091)
    • Connecticut
      • New Haven, Connecticut, Estados Unidos, 06519-1304
        • Winchester Chest Clinic ( Site 1093)
    • District of Columbia
      • Washington D.C., District of Columbia, Estados Unidos, 20037-3201
        • The George Washington University Medical Faculty Associates ( Site 1025)
    • Florida
      • Brandon, Florida, Estados Unidos, 33511
        • Bay Area Cardiology ( Site 1071)
      • Jacksonville, Florida, Estados Unidos, 32224
        • Mayo Clinic Jacksonville - PPDS ( Site 1045)
      • Orlando, Florida, Estados Unidos, 32803
        • AdventHealth Orlando ( Site 1058)
      • Tampa, Florida, Estados Unidos, 33606
        • Tampa General Hospital ( Site 1043)
    • Georgia
      • Atlanta, Georgia, Estados Unidos, 30309-1281
        • Piedmont Atlanta Hospital ( Site 1085)
      • Atlanta, Georgia, Estados Unidos, 30322-1013
        • Emory University ( Site 1030)
    • Idaho
      • Boise, Idaho, Estados Unidos, 83704-8880
        • Saint Alphonsus Regional Medical Center ( Site 1097)
    • Illinois
      • Chicago, Illinois, Estados Unidos, 60612
        • University of Illinois Hospital ( Site 1095)
    • Indiana
      • Indianapolis, Indiana, Estados Unidos, 46202-1218
        • IU Health Advanced Heart and Lung Care ( Site 1092)
      • Indianapolis, Indiana, Estados Unidos, 46260
        • Ascension Medical Group St. Vincent ( Site 1076)
    • Iowa
      • Iowa City, Iowa, Estados Unidos, 52242
        • University of Iowa Hospital and Clinics ( Site 1050)
    • Kansas
      • Kansas City, Kansas, Estados Unidos, 66160
        • University of Kansas Medical Center ( Site 1020)
    • Kentucky
      • Louisville, Kentucky, Estados Unidos, 40202
        • Norton Pulmonary Specialists ( Site 1066)
      • Louisville, Kentucky, Estados Unidos, 40202
        • University of Louisville ( Site 1099)
    • Louisiana
      • New Orleans, Louisiana, Estados Unidos, 70112
        • University Medical Center New Orleans ( Site 1057)
    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02111
        • Tufts Medical Center - PPDS ( Site 1012)
      • Boston, Massachusetts, Estados Unidos, 02115
        • Brigham and Women's Hospital [Boston, MA] ( Site 1014)
    • Michigan
      • Ann Arbor, Michigan, Estados Unidos, 48109
        • University of Michigan ( Site 1011)
    • Minnesota
      • Minneapolis, Minnesota, Estados Unidos, 55455
        • University of Minnesota Hospitals ( Site 1062)
    • Missouri
      • St Louis, Missouri, Estados Unidos, 63110
        • Washington University School of Medicine [Saint Louis, MO] ( Site 1022)
    • Nebraska
      • Omaha, Nebraska, Estados Unidos, 68198
        • University of Nebraska Medical Center ( Site 1053)
    • New York
      • Liverpool, New York, Estados Unidos, 13088
        • Pulmonary Health Physicians ( Site 1080)
      • New York, New York, Estados Unidos, 10021-9800
        • Weill Cornell Medical College ( Site 1046)
      • Rochester, New York, Estados Unidos, 14642
        • University of Rochester Medical Center - PPDS ( Site 1039)
    • North Carolina
      • Durham, North Carolina, Estados Unidos, 27710-4000
        • Duke University Medical Center ( Site 1026)
    • Ohio
      • Cincinnati, Ohio, Estados Unidos, 45219
        • The Carl and Edyth Lindner Center for Research and Education at the Christ Hospital ( Site 1001)
      • Cleveland, Ohio, Estados Unidos, 44106
        • University Hospitals Cleveland Medical Center ( Site 1005)
      • Cleveland, Ohio, Estados Unidos, 44195
        • Cleveland Clinic Foundation ( Site 1065)
      • Columbus, Ohio, Estados Unidos, 43210
        • The Ohio State University Wexner Medical Center ( Site 1032)
      • Toledo, Ohio, Estados Unidos, 43614
        • University of Toledo Medical Center ( Site 1070)
    • Oregon
      • Portland, Oregon, Estados Unidos, 97126
        • Oregon Health Science University ( Site 1054)
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Estados Unidos, 15212-4737
        • Allegheny General Hospital ( Site 1088)
      • Wynnewood, Pennsylvania, Estados Unidos, 19096
        • Lankenau Institute for Medical Research ( Site 1089)
    • Rhode Island
      • Providence, Rhode Island, Estados Unidos, 02903
        • Rhode Island Hospital ( Site 1033)
    • South Carolina
      • Charleston, South Carolina, Estados Unidos, 29425-0001
        • Medical University of South Carolina - PPDS ( Site 1003)
    • Tennessee
      • Knoxville, Tennessee, Estados Unidos, 37919
        • Statcare Pulmonary Consultants - Knoxville ( Site 1031)
    • Texas
      • Dallas, Texas, Estados Unidos, 75246
        • Baylor University Medical Center ( Site 1096)
      • Dallas, Texas, Estados Unidos, 75390
        • University of Texas Southwestern Medical Center ( Site 4002)
    • Utah
      • Murray, Utah, Estados Unidos, 84107
        • Intermountain Medical Center ( Site 1079)
    • Virginia
      • Falls Church, Virginia, Estados Unidos, 22042
        • Inova Heart and Vascular Institute ( Site 1078)
      • Richmond, Virginia, Estados Unidos, 23226
        • Bon Secours St. Mary's Hospital ( Site 1069)
    • West Virginia
      • Morgantown, West Virginia, Estados Unidos, 26506
        • West Virginia University ( Site 1081)
    • Wisconsin
      • Milwaukee, Wisconsin, Estados Unidos, 53215
        • Aurora St Luke's Medical Center ( Site 1083)
      • Milwaukee, Wisconsin, Estados Unidos, 53226
        • Froedtert Hospital & the Medical College of Wisconsin ( Site 1051)
  • França
    • Alpes-Maritimes
      • Nice, Alpes-Maritimes, França, 06000
        • Hôpital Pasteur - CHU Nice ( Site 1311)
    • Doubs
      • Besançon, Doubs, França, 25000
        • Centre Hospitalier Universitaire du Besancon ( Site 1324)
    • Haute-Garonne
      • Toulouse, Haute-Garonne, França, 31400
        • Hopital de Rangueil du Toulouse ( Site 1322)
    • Herault
      • Montpellier, Herault, França, 34090
        • CHU Montpellier Hôpital Arnaud de VIlleneuve ( Site 1301)
    • Ille-et-Vilaine
      • Rennes, Ille-et-Vilaine, França, 35033
        • Hôpital Pontchaillou ( Site 1319)
    • Isere
      • Grenoble, Isere, França, 38043
        • Centre Hospitalier Universitaire de Grenoble ( Site 1303)
    • Loire-Atlantique
      • Nantes, Loire-Atlantique, França, 44000
        • CHU de Nantes - Hoptal Nord Laennec ( Site 1309)
    • Maine-et-Loire
      • Angers, Maine-et-Loire, França, 49933
        • CHU Angers ( Site 1313)
    • Meurthe-et-Moselle
      • Vandœuvre-lès-Nancy, Meurthe-et-Moselle, França, 54500
        • CHRU de Nancy Hopitaux de Brabois ( Site 1308)
    • Nord
      • Lille, Nord, França, 59037
        • CHRU Lille ( Site 1306)
    • Seine-Maritime
      • Rouen, Seine-Maritime, França, 76000
        • CHU de Rouen ( Site 1323)
    • Val-de-Marne
      • Le Kremlin-Bicêtre, Val-de-Marne, França, 94270
        • Centre Hospitalier Universitaire de Bicetre ( Site 1304)
  • Israel
      • Ashdod, Israel, 7747629
        • Assuta Ashdod Medical Center ( Site 1710)
      • Be’er Ya‘aqov, Israel, 70300
        • Shamir Medical Center Assaf Harofeh ( Site 1713)
      • Haifa, Israel, 3436212
        • Lady Davis Carmel Medical Center ( Site 1705)
      • Haifa, Israel, 3109601
        • Rambam Health Corp. ( Site 1716)
      • Holon, Israel, 5810001
        • Edith Wolfson Medical Center ( Site 1717)
      • Jerusalem, Israel, 91031
        • Shaare Zedek Medical Center ( Site 1715)
      • Jerusalem, Israel, 91120
        • Hadassah Ein Kerem Medical Center ( Site 1711)
      • Kfar Saba, Israel, 4428164
        • Meir Medical Center. ( Site 1707)
      • Petah Tikva, Israel, 4941492
        • Rabin Medical Center ( Site 1703)
      • Rehovot, Israel, 7610001
        • Kaplan Medical Center ( Site 1712)
      • Safed, Israel, 13100
        • ZIV Medical Center ( Site 1704)
      • Tel Aviv, Israel, 64239
        • Tel Aviv Sourasky Medical Center ( Site 1714)
  • Itália
      • Bergamo, Itália, 24127
        • ASST Papa Giovanni XXIII ( Site 2410)
      • Roma, Itália, 00161
        • Azienda Policlinico Umberto I ( Site 2402)
    • Emilia-Romagna
      • Bologna, Emilia-Romagna, Itália, 40138
        • AOU di Bologna Policlinico S Orsola Malpighi ( Site 2409)
    • Friuli Venezia Giulia
      • Trieste, Friuli Venezia Giulia, Itália, 34149
        • Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI) ( Site 2405)
    • Lombardy
      • Monza, Lombardy, Itália, 20900
        • Fondazione IRCCS San Gerardo dei Tintori - ASST di Monza - A. O. San Gerardo ( Site 2406)
      • Pavia, Lombardy, Itália, 27100
        • Fondazione IRCCS-Policlinico San Matteo ( Site 2401)
    • Sardinia
      • Sassari, Sardinia, Itália, 07100
        • Ospedale SS Annunziata ( Site 2408)
  • México
    • Nuevo León
      • Monterrey, Nuevo León, México, 64710
        • Unidad de Investigacion Clinica En Medicina SC ( Site 2505)
  • Polônia
    • Lesser Poland Voivodeship
      • Krakow, Lesser Poland Voivodeship, Polônia, 31-202
        • Krakowski Szpital Specjalistyczny im Jana Pawla II ( Site 2801)
    • Lublin Voivodeship
      • Lubin, Lublin Voivodeship, Polônia, 20-718
        • Wojewodzki Szpital Specjalistyczny im Stefana Kardynala Wyszynskiego ( Site 2806)
    • Masovian Voivodeship
      • Otwock, Masovian Voivodeship, Polônia, 05-400
        • Europejskie Centrum Zdrowia Otwock Szpital im Fryderyka Chopina ( Site 2802)
      • Warsaw, Masovian Voivodeship, Polônia, 02-507
        • Państwowy Instytut Medyczny MSWiA ( Site 2805)
    • Podlaskie Voivodeship
      • Bialystok, Podlaskie Voivodeship, Polônia, 15-276
        • Uniwersytecki Szpital Kliniczny w Bialymstoku - Marii Sklodowskiej-Curie 24A ( Site 2803)
    • West Pomeranian Voivodeship
      • Szczecin, West Pomeranian Voivodeship, Polônia, 70-111
        • Samodzielny Publiczny Szpital Kliniczny Nr 2 PUM w Szczecinie ( Site 2804)
    • Łódź Voivodeship
      • Lodz, Łódź Voivodeship, Polônia, 91-347
        • Wojewodzki Specjalistyczny Szpital im dr WI Bieganskiego w Lodzi ( Site 2807)
  • Reino Unido
    • London, City of
      • London, London, City of, Reino Unido, W12 0HS
        • Imperial College Healthcare NHS Trust ( Site 1203)
  • Suécia
    • Västra Götaland County
      • Gothenburg, Västra Götaland County, Suécia, 413 45
        • Sahlgrenska Universitetssjukhuset ( Site 3201)

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 85 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

Participants must meet the following criteria to be enrolled in this proof-of-concept study:

  1. Age 18 to 85 years

  2. Clinical diagnosis of HFpEF:

    • Left ventricular ejection fraction ≥50%, with no history of LVEF below 45% in more than two consecutive measurements under stable conditions

  3. Demonstrated Cpc-PH by all of the following:

    • Baseline RHC performed within 28 days of randomization documenting a minimum PVR of ≥320 dyn•sec/cm5 (4 wood units)
    • Mean pulmonary arterial pressure (mPAP) of >20 mmHg
    • Pulmonary capillary wedge pressure (PCWP) >15 mmHg but < 30 mmHg

  4. New York Heart Association FC of II or III

  5. Six-minute Walk Distance ≥100 m repeated twice during Screening and both values within 15% of each other, calculated from the highest value

  6. Chronic medication for HF or for any underlying condition, administered at a stable (per investigator) dose for ≥30 days prior to Visit 1. Diuretics and/or anticoagulants are excepted from this rule but should not be newly started or stopped within 30 days of Visit 1, and a prescribed dose change should not occur within 7 days of Visit 1. Anticoagulation may be suspended for RHC if necessary

  7. Women of childbearing potential must:

    • Have 2 negative urine or serum pregnancy tests as verified by the investigator during the Screening Period; must agree to ongoing pregnancy testing during the course of the study and until 8 weeks after the last dose of the study drug
    • If sexually active with a male partner: use highly effective contraception without interruption for at least 28 days prior to starting the investigational product AND agree to use the same highly effective contraception in combination with a barrier method during the study (including dose interruptions), and for 16 weeks (112 days) after discontinuation of study treatment
    • Refrain from breastfeeding a child or donating blood, eggs, or ovum for the duration of the study and for at least 16 weeks (112 days) after the last dose of study drug

  8. Male participants must:

    • Agree to use a condom, defined as a male latex condom or non latex condom NOT made out of natural (animal) membrane (e.g., polyurethane), during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions, and for at least 16 weeks (112 days) following investigational product discontinuation, even if he has undergone a successful vasectomy
    • Refrain from donating blood or sperm for the duration of the study and for 16 weeks (112 days) after the last dose of study drug

  9. Ability to adhere to the study visit schedule and understand and comply with all protocol requirements

  10. Agreement to not participate in any other trials of investigational drugs/devices while enrolled in the A011-16 study

  11. Ability to understand and provide documented consent for participation

Exclusion Criteria:

Participants will be excluded from the study if any of the following criteria are met:

  1. A diagnosis of PH in WHO Group 1, WHO Group 3, WHO Group 4, or WHO Group 5

  2. Clinically significant and active lung disease:

    • Chronic obstructive pulmonary disease with post-bronchodilator forced expiratory volume in the first second (FEV1) <60% predicted
    • Restrictive lung disease with total lung capacity <70% predicted
    • More than mild interstitial lung disease (ILD), with FVC<70% or FEV1<60% predicted (still appropriate if absence of more than mild ILD, fibrosis, or COPD on computed tomography [CT] imaging)

  3. Cardiovascular co-morbidities, which include any of the following:

    • History of more than mild mitral or aortic stenosis
    • Ongoing more than mild mitral or aortic regurgitation
    • More than one valve replacement or repair (mechanical or biomechanical) or anticipation of any valve replacement or repair
    • Severe tricuspid regurgitation due to primary valvular disease
    • Occurrence of myocardial infarction, acute coronary syndrome, coronary artery bypass graft or percutaneous coronary intervention within 180 days of Visit 1
    • History of serious life-threatening or hemodynamically significant arrhythmia
    • History of or anticipated heart transplant or ventricular assist device implantation
    • History of implantable cardioverter defibrillator placement or anticipated implantation of pacemaker, pacemaker implantation within 30 days of Screening
    • Anticipated implantation of pacemaker, pacemaker implantation within 30 days of Screening or history of implantable cardioverter defibrillator placement
    • Occurrence of myocardial infarction within 180 days of Visit 1
    • History of known pericardial constriction, hypertrophic cardiomyopathy, sarcoidosis, or amyloid cardiomyopathy
    • Uncontrolled systemic hypertension as evidenced by sitting systolic blood pressure >160 mmHg or sitting diastolic blood pressure >110 mmHg during Screening after a period of rest
    • Systemic hypotension as evidenced by sitting systolic blood pressure <90 mmHg or sitting diastolic blood pressure <50 mmHg during Screening
    • Resting heart rate of <45 bpm or >115 bpm
    • Stroke within 90 days of Visit 1
    • Acutely decompensated HF that required hospitalization within 30 days of Visit 1
    • Electrocardiogram during Screening Period with Fridericia's corrected QT interval (QTcF) >470 msec for males or >480 msec for females, or >500 msec if a ventricular conduction defect (right bundle branch block; left bundle branch block; or interventricular conduction delay) is present
    • Personal or family history of Brugada syndrome, sudden cardiac arrest or unexplained sudden cardiac death or arrest
    • Personal or family history of long QT syndrome unless the participant's ECG shows a normal QTc
    • Arrhythmogenic right ventricular dysplasia (ARVD) unless the participant has a recent cardiac MRI that shows no evidence of this diagnosis

  4. Hospitalization for any worsening of medical conditions or any significant surgery per investigator within 30 days of Visit 1

  5. Received any approved PAH-specific therapies (i.e., endothelin receptor antagonists, prostacyclin analogs, phosphodiesterase-5 inhibitors, soluble guanylate cyclase stimulators) within 30 days of Visit 1.The use of an oral phosphodiesterase type 5 inhibitor, if only indicated for erectile dysfunction, is permitted, if not administered within 48 hours of a study visit or procedure

  6. Received intravenous inotropes (e.g., dobutamine, dopamine, norepinephrine, vasopressin, or levosimendan) within 30 days of Visit 1

  7. Received erythropoietin within 6 months of Visit 1

  8. Known history of chronic liver disease, including untreated hepatitis B and/or hepatitis C (with evidence of recent infection and/or active virus replication), with severe hepatic impairment and/or cirrhosis (e.g., hepatic encephalopathy)

  9. Prior exposure to sotatercept or luspatercept

  10. Currently enrolled in or have completed any other investigational product study within 30 days for small molecule drugs or within 5 half-lives for investigational biologics prior to the date of documented consent

  11. Initiation of an exercise program for cardiopulmonary rehabilitation within 90 days of Visit 1 or planned initiation during the study (participants who are stable in the maintenance phase of a program and who will continue for the duration of the study are eligible)

  12. Any of the following clinical laboratory values prior to Visit 1 as specified:

    • Hemoglobin (Hgb) above the gender-specific upper limit of normal (ULN) per local laboratory test within 28 days of Visit 1or <10 g/dL per local laboratory within 28 days of Visit 1
    • Serum alanine aminotransferase or aspartate aminotransferase levels >3× ULN or total bilirubin >3× ULN within 28 days of Visit 1
    • Estimated glomerular filtration rate <30 ml/min/1.73 m2 (4-variable Modification of Diet in Renal Disease equation) within 28 days of Visit 1 or required renal replacement therapy within 90 days of Visit 1
    • Glycated hemoglobin (HbA1c) >10% within 28 days of Visit 1
    • Platelet count < 75,000/mm3 within 28 days of Visit 1

  13. History of severe allergic or anaphylactic reaction or hypersensitivity to recombinant proteins or excipients in the investigational product

  14. Major surgery within 60 days of Visit 1. Participants must have completely recovered from any previous surgery prior to Visit 1

  15. Prior organ transplantation (e.g., heart, lung, liver, kidney), bone marrow transplantation, or life expectancy of < 12 months

  16. Pregnancy or breastfeeding in females

  17. Active malignancy, with the exception of fully excised or treated basal cell carcinoma, cervical carcinoma in situ, or ≤ 2 squamous cell carcinomas of the skin

  18. History of clinically significant (as determined by the investigator) endocrine, hematologic, hepatic, (auto)immune, infectious (requiring chronic antibiotics), metabolic, urologic, pulmonary, neurologic, neuromuscular, dermatologic, psychiatric, renal, and/or another disease that may limit participation in the study

  19. Body mass index ≥50 kg/m2

  20. More than mild obstructive sleep apnea (treated or untreated)

  21. Any non-cardiopulmonary condition or acute/chronic impairment(s) (other than dyspnea) that limits the ability to perform 6-minute walk test (6MWT)

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Triplo

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Comparador de Placebo: Placebo

Delivered subcutaneously (SC) every 3 weeks (Q3W) for 24 weeks in the placebo-controlled treatment period.
Medicamento: Placebo

Administered by subcutaneous injection
Experimental: Sotatercept 0.3 mg/kg

Participants will receive sotatercept SC at a dose level of 0.3 mg/kg Q3W for 24 weeks in the placebo-controlled treatment period.
Medicamento: Sotatercept 0.3 mg/kg

Administered by subcutaneous injection. Sotatercept (ACE-011) is a recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA linked to the Fc piece of human IgG1.

Outros nomes:
  • ACE-011
Experimental: Sotatercept 0.3 mg/kg, escalating to 0.7 mg.kg

Sotatercept SC at a starting dose level of 0.3 mg/kg for 3 dosing visits (Q3W), then escalating to 0.7 mg/kg SC on the fourth dosing visit and Q3W for the remainder of the 24-week treatment Period.
Medicamento: Sotatercept 0.3 mg/kg escalating to 0.7 mg/kg

Administered by subcutaneous injection. Sotatercept (ACE-011) is a recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA linked to the Fc piece of human IgG1.

Outros nomes:
  • ACE-011

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Base Study: Change From Baseline in Pulmonary Vascular Resistance (PVR) at Week 24
Prazo: Baseline and Week 24

PVR, a hemodynamic variable of pulmonary circulation, was measured by right heart catheterization (RHC). Participants missing a value at baseline were excluded from the analysis. Participants missing a value at Week 24 (other than death or experienced a clinical worsening event), multiple imputation was used to impute missing data. Participants who died, the worst-rank score was assigned. Participants missing a value at Week 24 due to a clinical worsening event, the next-worst-rank score was used. The 'Full Range' is the minimum and maximum of the 100 medians from the 100 imputed datasets.
Baseline and Week 24

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Base Study: Change From Baseline in the 6-Minute Walk Distance (6MWD) at Week 24
Prazo: Baseline and Week 24

The 6MWD was performed to assess functional capacity. The 6MWD was assessed using the 6-minute walk test (6MWT) to measure the distance covered over a time period of 6 minutes. An increase in the distance walked during the 6MWT indicated improvement in functional exercise capacity. Participants missing a value at baseline were excluded from the analysis. Participants missing a value at Week 24 (other than death or experienced a clinical worsening event), multiple imputation was used to impute missing data. Participants who died, the worst-rank score was assigned. Participants missing a value at Week 24 due to a clinical worsening event, the next-worst-rank score was used. The 'Full Range' is the minimum and maximum of the 100 medians from the 100 imputed datasets.
Baseline and Week 24
Base Study: Time to First Clinical Worsening Event (TTCW) at Weeks 24
Prazo: 24 Weeks

Clinical Worsening events were defined as the number of weeks from first dose date to any of the following:

  • Hospitalization due to a cardiopulmonary indication (a non-elective hospitalization lasting at least 24 hours in duration caused by clinical conditions directly related to Pulmonary Hypertension and/or Heart Failure)
  • Administration of intravenous diuretics or subcutaneous (SC) furosemide
  • Death (all causes)
  • Decrease in 6 minute walk distance (6MWD) by ≥15% from baseline confirmed by 2 tests at least 4hours, but no more than 1 week apart.
24 Weeks
Base Study: Change From Baseline in Mean Pulmonary Arterial Pressure (mPAP) at Week 24
Prazo: Baseline and Week 24

mPAP was calculated from systolic and diastolic pulmonary artery pressure measured by right heart catheterization. Participants missing a value at baseline were excluded from the analysis. Participants missing a value at Week 24 (other than death or experienced a clinical worsening event), multiple imputation was used to impute missing data. Participants who died, the worst-rank score was assigned. Participants missing a value at Week 24 due to a clinical worsening event, the next-worst-rank score was used. The 'Full Range' is the minimum and maximum of the 100 medians from the 100 imputed datasets.
Baseline and Week 24
Base Study: Change From Baseline in Pulmonary Capillary Wedge Pressure (PCWP) at Week 24
Prazo: Baseline and Week 24

PCWP is an indirect estimate of left atrial pressure measured in right heart catheterization. Participants missing a value at baseline were excluded from the analysis. Participants missing a value at Week 24 (other than death or experienced a clinical worsening event), multiple imputation was used to impute missing data. Participants who died, the worst-rank score was assigned. Participants missing a value at Week 24 due to a clinical worsening event, the next-worst-rank score was used. The 'Full Range' is the minimum and maximum of the 100 medians from the 100 imputed datasets.
Baseline and Week 24
Base Study: Change From Baseline in Tricuspid Annular Plane Systolic Excursion (TAPSE) at Week 24
Prazo: Baseline and Week 24

TAPSE is an echocardiographic measurement of tricuspid valve annulus movement, as an indicator of right heart function. Participants missing a value at baseline were excluded from the analysis. Participants missing a value at Week 24 (other than death or experienced a clinical worsening event), multiple imputation was used to impute missing data. Participants who died, the worst-rank score was assigned. Participants missing a value at Week 24 due to a clinical worsening event, the next-worst-rank score was used. The 'Full Range' is the minimum and maximum of the 100 medians from the 100 imputed datasets.
Baseline and Week 24
Base Study: Change From Baseline in Right Ventricular Fractional Area Change (RVFAC) at Week 24
Prazo: Baseline and Week 24

RVFAC is an echocardiographic measurement of percent change between right ventricular area during diastole and systole, as an indicator of right heart function. Participants missing a value at baseline were excluded from the analysis. Participants missing a value at Week 24 (other than death or experienced a clinical worsening event), multiple imputation was used to impute missing data. Participants who died, the worst-rank score was assigned. Participants missing a value at Week 24 due to a clinical worsening event, the next-worst-rank score was used. The 'Full Range' is the minimum and maximum of the 100 medians from the 100 imputed datasets.
Baseline and Week 24
Base Study: Change From Baseline in Left Ventricular Ejection Fraction (LVEF) at Week 24
Prazo: Baseline and Week 24

LVEF is an echocardiographic measurement of percent change between left ventricular volume during diastole and systole, as an indicator of left heart function. Participants missing a value at baseline were excluded from the analysis. Participants missing a value at Week 24 (other than death or experienced a clinical worsening event), multiple imputation was used to impute missing data. Participants who died, the worst-rank score was assigned. Participants missing a value at Week 24 due to a clinical worsening event, the next-worst-rank score was used. The 'Full Range' is the minimum and maximum of the 100 medians from the 100 imputed datasets.
Baseline and Week 24
Base Study: Change From Baseline in Isovolumic Relaxation Time (IVRT) at Week 24
Prazo: Baseline and Week 24

IVRT is an echocardiographic measurement of the interval between closure of the aortic valve, to onset of filling by opening of the mitral valve. It was used as an indicator of diastolic dysfunction. Participants missing a value at baseline were excluded from the analysis. Participants missing a value at Week 24 (other than death or experienced a clinical worsening event), multiple imputation was used to impute missing data. Participants who died, the worst-rank score was assigned. Participants missing a value at Week 24 due to a clinical worsening event, the next-worst-rank score was used. The 'Full Range' is the minimum and maximum of the 100 medians from the 100 imputed datasets.
Baseline and Week 24
Base Study: Change From Baseline in Ratio of Mitral Inflow Velocity E to Mitral Annular Velocity'(e') (E/e' Ratio) at Week 24
Prazo: Baseline and Week 24

E/e' is a ratio of mitral inflow velocity E to mitral annular velocity (e') as measured by electrocardiography as an indicator of diastolic function. Participants missing a value at baseline were excluded from the analysis. Participants missing a value at Week 24 (other than death or experienced a clinical worsening event), multiple imputation was used to impute missing data. Participants who died, the worst-rank score was assigned. Participants missing a value at Week 24 due to a clinical worsening event, the next-worst-rank score was used. The 'Full Range' is the minimum and maximum of the 100 medians from the 100 imputed datasets.
Baseline and Week 24
Base Study: Change From Baseline in the Ratio of the Peak Velocity Flow of the E Wave in Early Diastole to Peak Velocity Flow of the A Wave in Late Diastole (E/A Ratio) at Week 24
Prazo: Baseline and Week 24

E/A is a ratio of the peak velocity flow of the E wave in the early diastole to peak velocity flow of the A wave in late diastole measured by echocardiography as an indicator of diastolic function. Participants missing a value at baseline were excluded from the analysis. Participants missing a value at Week 24 (other than death or experienced a clinical worsening event), multiple imputation was used to impute missing data. Participants who died, the worst-rank score was assigned. Participants missing a value at Week 24 due to a clinical worsening event, the next-worst-rank score was used. The 'Full Range' is the minimum and maximum of the 100 medians from the 100 imputed datasets.
Baseline and Week 24
Base Study: Change From Baseline in N-terminal Pro-hormone Brain Natriuretic Peptide (NT-proBNP) at Week 24
Prazo: Baseline and Week 24

NT-proBNP is a circulating biomarker that reflects myocardial stretch. Participants missing a value at baseline were excluded from the analysis. Participants missing a value at Week 24 (other than death or experienced a clinical worsening event), multiple imputation was used to impute missing data. Participants who died, the worst-rank score was assigned. Participants missing a value at Week 24 due to a clinical worsening event, the next-worst-rank score was used. The 'Full Range' is the minimum and maximum of the 100 medians from the 100 imputed datasets.
Baseline and Week 24
Base Study: Change From Baseline in New York Heart Association Functional Class (NYHA FC) at Week 24
Prazo: Baseline and Week 24

NYHA FC classified the extent of heart failure (HF). Participant HF symptoms were graded using the NYHA FC system. NYHA FC for HF ranges from Class I (no limitation of physical activity, or ordinary physical activity does not cause undue fatigue, palpitation, dyspnea [shortness of breath]), Class II (slight limitation of physical activity, comfortable at rest, or ordinary physical activity results in fatigue, palpitation, dyspnea [shortness of breath]), Class III (marked limitation of physical activity, comfortable at rest, or less than ordinary activity causes fatigue, palpitation, or dyspnea) and Class IV (unable to carry on any physical activity without discomfort, symptoms of HF at rest or if any physical activity is undertaken, discomfort increases). Participants were classified as "Improved or Maintained" or "Not Improved nor Not Maintained". Improved or Maintained = reduction in NYHA FC or no change in NYHA FC; Not Improved nor Not Maintained = increase in NYHA FC.
Baseline and Week 24
Base Study: Change From Baseline in Myocardial Contraction Fraction (MCF) at Week 24
Prazo: Baseline and Week 24

MCF is an echocardiographic measurement that determined the ratio of left ventricular stroke volume to myocardial volume and was an indicator of left ventricular systolic function. Participants missing a value at baseline were excluded from the analysis. Participants missing a value at Week 24 (other than death or experienced a clinical worsening event), multiple imputation was used to impute missing data. Participants who died, the worst-rank score was assigned. Participants missing a value at Week 24 due to a clinical worsening event, the next-worst-rank score was used. The 'Full Range' is the minimum and maximum of the 100 medians from the 100 imputed datasets.
Baseline and Week 24
Base Study: Number of Participants With One or More Adverse Events (AEs)
Prazo: Up to approximately 6 months

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experienced an AE was reported.
Up to approximately 6 months
Base Study: Number of Participants Who Discontinued Study Treatment Due to an AE
Prazo: Up to approximately 6 months

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experienced an AE was reported.
Up to approximately 6 months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA

Investigadores

  • Diretor de estudo: Medical Director, Merck Sharp & Dohme LLC

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Publicações Gerais

Links úteis

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

29 de dezembro de 2021

Conclusão Primária (Real)

5 de setembro de 2025

Conclusão do estudo (Real)

9 de abril de 2026

Datas de inscrição no estudo

Enviado pela primeira vez

11 de junho de 2021

Enviado pela primeira vez que atendeu aos critérios de CQ

22 de junho de 2021

Primeira postagem (Real)

30 de junho de 2021

Atualizações de registro de estudo

Última Atualização Postada (Real)

23 de setembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

28 de agosto de 2026

Última verificação

1 de agosto de 2026

Mais Informações

Termos relacionados a este estudo

Palavras-chave

Termos MeSH relevantes adicionais

Outros números de identificação do estudo

  • 7962-007
  • A011-16 (Outro identificador: Acceleronpharma)
  • MK-7962-007 (Outro identificador: MSD)
  • 2021-003020-32 (Número EudraCT)
  • U1111-1309-6433 (Identificador de registro: UTN)
  • 2023-509141-12-00 (Identificador de registro: EU CT)
  • 2023 (Concessão/Contrato do NIH dos EUA)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever